Stocks making the biggest moves midday: Meta Platforms, Brown-Forman, Amazon, Marvell & more

Simply Good Foods plunged 19% after Q2 revenue, adjusted EBITDA and Q3 guidance missed Street expectations. Brown-Forman jumped 12% on a reported Sazerac approach (coming after confirmed talks with Pernod Ricard), while software stocks sold off (IGV -~4%; Cloudflare -11%, Okta -7%, CrowdStrike -5%) after Anthropic rolled out Claude Managed Agents. Marvell gained 5% to a 52-week high after a Barclays upgrade and $150 PT, Meta rose ~4% alongside an incremental $21B CoreWeave infrastructure deal (on top of a prior $14.2B), and Amazon jumped ~5% on plans to distribute Eli Lilly’s Foundayo in >3,000 cities (targeting 4,500 by end-2026). Staar Surgical guided Q1 revenue >$90M (vs $67.6M FactSet), Constellation beat Q4 EPS $1.90 vs $1.72 and revenue $1.92B vs $1.88B, and Zscaler fell ~9% after a downgrade.

Analysis

M&A chatter in consolidated consumer categories tends to reprice both target and peer groups well ahead of deal closure; acquirers often tighten gross margins via supply-chain rationalization, which in turn pressures third-party co-packers and packaging suppliers within 3–12 months. Conversely, niche premium brands benefit from multiple expansion if buyers prize distribution scale over margin.

The recent wave of agentized AI and managed agent platforms creates a two-speed software market: vendors with low-latency, GPU-optimized inference/infrastructure exposure win share quickly, while traditional SaaS vendors with high retention but limited productized AI risk seeing churn accelerate as customers re-platform. Expect earnings guide-downs to show up over the next two reporting cycles for carriers of legacy architectures — a forward-looking NRR decline is the earliest signal.

Retail rollouts of high-demand therapeutics via same-day logistics are a structural demand amplifier for urban logistics and last-mile compute/fulfillment, compressing delivery unit economics in high-density corridors and forcing margin trade-offs for players that internalize pharmacy distribution. Regulatory scrutiny and inventory management will be the primary near-term reversal risks, with real constraint points appearing within 6–18 months as volume scales.

Taken together, the market is bifurcating between capital-intensive infra plays that earn higher incremental margins from AI scale and software incumbents exposed to product substitution; that suggests pair trades hedging macro beta while expressing selective secular exposure to AI compute and logistics capture economics.

Key Decisions for Investors

• Long MRVL (stock) 6–12 months: target +30% if market re-prices infra-on-GPU winners; downside -15% on broader semiconductor multiple compression. Size 2–3% of portfolio, add on pullbacks to 10% below entry.
• Long CRWV (or Core infra provider exposure) via 12–18 month call spread to cap premium: buy 2027 LEAP call, sell higher strike to fund cost. Reward: asymmetric capture of infra deal rollouts; risk limited to premium paid. Use for portfolio allocation to AI capacity growth.
• Pair trade — Long NVDA (or proxied infra) / Short GTLB (or weak NRR SaaS name) over 3–9 months: size 1.5/1. Short targets are those showing early NRR deterioration; long leg benefits from continued AI capex. Close if spread compresses by 20% or if NRR on short rebounds materially.
• Event-driven short for select consumer names showing material guide-down risk: initiate small-size short or buy puts 0–6 months ahead of next quarter guidance release, target 25–40% downside on miss, stop-loss at 20% adverse move. This trades earnings cadence and guide risk without broad market exposure.